Login to MyKarger

New to MyKarger? Click here to sign up.

Login with Facebook

Forgot Password? Reset your password

Authors, Editors, Reviewers

For Manuscript Submission, Check or Review Login please go to Submission Websites List.

Submission Websites List

Institutional Login (Shibboleth)

For the academic login, please select your country in the dropdown list. You will be redirected to verify your credentials.

Table of Contents
Vol. 33, No. 3, 2003
Issue release date: May – June
Section title: Original Paper
Pathophysiol Haemost Thromb 2003;33:121–126

Influence of a Long-Term, High-Dose Volume Therapy with 6% Hydroxyethyl Starch 130/0.4 or Crystalloid Solution on Hemodynamics, Rheology and Hemostasis in Patients with Acute Ischemic Stroke

Results of a Randomized, Placebo-Controlled, Double-Blind Study

Woessner R.a · Grauer M.T.a · Dieterich H.-J.b · Bepperling F.c · Baus D.c · Kahles T.d · Georgi S.d · Bianchi O.d · Morgenthaler M.a · Treib J.a
aDepartment of Neurology, Westpfalz Klinikum, University City of Kaiserslautern, Kaiserslautern, bDepartment of Anaesthesiology, University of Tübingen, Tübingen, cDepartment of Clinical Research, Fresenius Kabi, Deutschland GmbH, Bad Homburg, dDepartment of Neurology, University of the Saarland, Homburg/Saar, Germany
email Corresponding Author

Priv.-Doz. Dr. med. Johannes Treib, MD

Department of Neurology

Westpfalz-Klinikum GmbH, University Teaching Hospital

DE–67655 Kaiserslautern (Germany)

Tel. +49 631 203 1792, Fax +49 631 203 1977, E-Mail jtreib@westpfalz-klinikum.de


  1. Baron J-F, Treib J (eds): Volume Replacement. Berlin, Springer, 1998.
  2. Treib J (ed): Volume Therapy. Berlin, Springer, 2000.
  3. Treib J, Grauer MT, Woessner R, Morgenthaler M: Treatment of stroke on an intensive stroke unit: A novel concept. Intensive Care Med 2000;26:1598–1611.
  4. Mast H, Marx P: Neurological deterioration under isovolemic hemodilution with hydroxyethyl starch in acute cerebral ischemia. Stroke 1991;22:680–683.
  5. Haemodilution in acute stroke: Results of the Italian haemodilution trial. Italian Acute Stroke Study Group. Lancet 1988;i:318–321.
  6. Aichner FT, Fazekas F, Brainin M, Polz W, Mamoli B, Zeiler K: Hypervolemic hemodilution in acute ischemic stroke: The Multicenter Austrian Hemodilution Stroke Trial (MAHST). Stroke 1998;29:743–749.
  7. Koller M, Haenny P, Hess K, Weniger D, Zangger P: Adjusted hypervolemic hemodilution in acute ischemic stroke. Stroke 1990;21:1429–1434.
  8. Strand T: Evaluation of long-term outcome and safety after hemodilution therapy in acute ischemic stroke. Stroke 1992;23:657–662.
  9. Strand T, Asplund K, Eriksson S, Hägg E, Lithner F, Wester PO: A randomized controlled trial of hemodilution therapy in acute ischemic stroke. Stroke 1984;15:980–989.
  10. Hypervolemic hemodilution treatment of acute stroke. Results of a randomized multicenter trial using pentastarch. The Hemodilution in Stroke Study Group. Stroke 1989;20:317–323.
  11. Kaplan S, Park TS, Gonzales E, Gidday J: Hydroxyethyl starch reduces leukocyte adherence and vascular injury in the newborn pig cerebral circulation after asphyxia. Stroke 2000;31:2218–2223.
  12. Treib J, Baron JF, Grauer MT, Strauss RG: An international view of hydroxyethyl starches. Intensive Care Med 1999;25:258–268.
  13. Treib J, Haass A, Pindur G: Coagulation disorders caused by hydroxyethyl starch. Thromb Haemost 1997;78:974–983.
  14. Treib J, Haass A, Pindur G, Grauer MT, Wenzel E, Schimrigk K: All medium starches are not the same: Influence of the degree of hydroxyethyl substitution of hydroxyethyl starch on plasma volume, hemorrheologic conditions and coagulation. Transfusion 1996;36:450–455.
  15. Treib J, Haass A, Pindur G, Seyfert UT, Treib W, Grauer MT, Jung F, Wenzel E, Schimrigk K: HES 200/0.5 is not HES 200/0.5. Influence of the C2/C6 hydroxyethylation ratio of hydroxyethyl starch (HES) on hemorheology, coagulation and elimination kinetics. Thromb Haemost 1995;74:1452–1456.
  16. Treib J, Haass A, Krammer I, Stoll M, Grauer MT, Schimrigk K: Cardiac output in patients with acute stroke. J Neurol 1996;243:575–578.
  17. Rudolf J: Hydroxyethyl starch for hypervolemic hemodilution in patients with acute ischemic stroke: A randomized, placebo-controlled phase II safety study. Cerebrovasc Dis 2002;14:33–41.
  18. Waitzinger J, Bepperling F, Pabst G, Opitz J, Müller M, Baron JF: Pharmacokinetics and tolerability of a new hydroxyethyl starch (HES) specification (HES 130/0.4) after single-dose infusion of 6% or 10% solutions in healthy volunteers. Clin Drug Invest 1998;16:151–160.
  19. Waitzinger J, Bepperling F, Pabst G, Opitz J, Fackelmeyer A, Boldt J: Effect of a new hydroxyethyl starch (HES) specification (6% HES 130/0.4) on blood and plasma volumes after bleeding in 12 healthy male volunteers. Clin Drug Invest 1999;17:119–125.
  20. Waitzinger J, Bepperling F, Pabst G, Opitz J: Hydroxyethyl starch (HES) [130/0.4], a new HES specification: Pharmacokinetics and safety after multiple infusions of 10% solution in healthy volunteers. Drug R D 2003;4:149–157.
  21. Langeron O, Doelberg M, Ang ET, Bonnet F, Capdevila X, Coriat P: Voluven, a lower substituted novel hydroxyethyl starch (HES 130/0.4), causes fewer effects on coagulation in major orthopedic surgery than HES 200/0.5. Anesth Analg 2001;92:855–862.
  22. Leuschner J, Opitz J, Winkler A, Scharpf R, Bepperling F: Tissue storage of 14C-labelled hydroxyethyl starch (HES 130/0.4) and HES 200/0.5 after repeated intravenous administration to rats. Drugs R D 2003;4:331–338.
  23. Gröchenig E, Albegger K, Dieterich HJ, et al: Hydroxyethylstarch-related pruritus: A prospective multicenter investigation of 544 patients. Perfusion 1998;11:62–69.